Patents Assigned to GlaxoSmithKline Biological S.A.
  • Purification of streptococcal capsular polysaccharide
    Patent number: 10172928
    Abstract: A purification method for the capsular polysaccharide of type II GBS in which the capsular polysaccharide is filtered using a membrane with a cut-off of less than 30 kDa.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: January 8, 2019
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Francesco Berti, Paolo Costantino, Maria Rosaria Romano
  • Immunogenic composition
    Patent number: 10166287
    Abstract: present application discloses an immunogenic composition comprising N. meningitidis capsular polysaccharides from at least one of serogroups A, C, W135 and Y conjugated to a carrier protein to produce a N. meningitidis capsular polysaccharide conjugate, wherein the average size of each N. meningitidis polysaccharide is above 50 kDa.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: January 1, 2019
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Ralph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
  • Compositions and methods for protein glycosylation
    Patent number: 10150952
    Abstract: Described herein are oligosaccharyl transferases for use in N-glycosylating proteins of interest in vitro and in host cells. Methods for using such oligosaccharyl transferases, nucleic acids encoding such oligosaccharyl transferases, and host cells comprising such oligosaccharyl transferases are also provided herein. Glycoconjugates generated by using such oligosaccharyl transferases are also provided herein.
    Type: Grant
    Filed: December 24, 2015
    Date of Patent: December 11, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Jurgen Haas, Julian Ihssen, Michael Thomas Kowarik, Torsten Franz Schwede, Linda Christiane Thöny-Meyer
  • Immunogenic composition
    Patent number: 10130694
    Abstract: The present invention relates to immunogenic compositions comprising a Clostridium difficile (C. difficile) polypeptide and an aluminum-free adjuvant.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: November 20, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Dominique Boutriau, Sophie Marie Jeanne Valentine Germain, Hugues Wallemacq
  • LIPOSOME PRODUCTION USING ISOPROPANOL
    Publication number: 20180303940
    Abstract: Provided are compositions and methods for producing a lipidic film. The method comprises the steps of: (i) dissolving a lipid mix in isopropanol to form a homogeneous mix; and (ii) removing the solvent from the homogeneous mix to form a lipidic film, wherein the lipid mix comprises a lipid and cholesterol.
    Type: Application
    Filed: June 27, 2018
    Publication date: October 25, 2018
    Applicant: GLAXOSMITHKLINE BIOLOGICALS, S.A.
    Inventors: Carine DE KESEL, Vincent MANCUSO
  • Method for preventing or treating infection
    Patent number: 10105430
    Abstract: The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: October 23, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS, S.A.
    Inventor: Martine Marchand
  • Adsorption of immunopotentiators to insoluble metal salts
    Patent number: 10098949
    Abstract: Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminum salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: October 16, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Manmohan Singh, David A. G. Skibinksi, Tom Yao-Hsiang Wu, Yongkai Li, Alex Cortez, Xiaoyue Zhang, Yefen Zou, Timothy Z. Hoffman, Jianfeng Pan, Kathy Yue
  • Nucleotide sequences, vectors and host cells
    Patent number: 10093722
    Abstract: The present invention relates to fusion proteins comprising fragments from toxin A and/or toxin B of Clostridium difficile, wherein the polypeptide elicits antibodies that neutralize toxin A or toxin B or both.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: October 9, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventor: Cindy Castado
  • EXPRESSION SYSTEM
    Publication number: 20180258146
    Abstract: Methods for producing a conjugate of a bacterial toxin, including diphtheria toxin or CRM197, are provided.
    Type: Application
    Filed: May 8, 2018
    Publication date: September 13, 2018
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Normand BLAIS, Philippe Marc Helene DEHOTTAY, Marianne DEWERCHIN, Philippe GOFFIN, Denis MARTIN
  • Integration of meningococcal conjugate vaccination
    Patent number: 10064932
    Abstract: The invention provides a method for immunizing a patient, comprising administering multiple conjugates meningococcal capsular saccharides, wherein each conjugate comprises a diphtheria toxoid (or derivative thereof) carrier protein, and the capsular saccharide, and wherein the patient has been pre-immunized with a diphtheria toxoid (or derivative thereof).
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: September 4, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventor: Cameron John Marshall
  • Method for determining the endotoxin content of an aluminum salt preparation
    Patent number: 10060928
    Abstract: Methods for determining the endotoxin content of an aluminum salt preparation for use in medicine are provided. The methods include mixing the aluminum salt with a desorption buffer and separating the aluminum salt from the endotoxin.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: August 28, 2018
    Assignee: GlaxoSmithKline Biologicals, S.A.
    Inventor: Clementine Mascaux
  • Vaccine
    Patent number: 10058603
    Abstract: The disclosure provides immunogenic compositions comprising human picornavirus peptides derived from structural proteins of the virus, constructs comprising the peptides, the peptides themselves and their use in the prevention of picornavirus infection and disease. Particular peptides from VP4 and VP1 are disclosed.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: August 28, 2018
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Guy Baudoux, Mathieu Boxus, Brigitte Colau, Martine Marchand
  • Homogenous suspension of immunopotentiating compounds and uses thereof
    Patent number: 10046048
    Abstract: The present invention generally relates to homogeneous suspensions of small molecule immune potentiators (SMIPs) that are capable of stimulating or modulating an immune response in a subject in need thereof. The homogeneous suspensions may be used in combinations with various antigens or adjuvants for vaccine therapies.
    Type: Grant
    Filed: July 5, 2016
    Date of Patent: August 14, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: David Skibinksi, Siddhartha Jain, Manmohan Singh, Derek O'Hagan
  • USE OF ALPHA-TOXIN FOR TREATING AND PREVENTING STAPHYLOCOCCUS INFECTIONS
    Publication number: 20180221466
    Abstract: Vaccines comprising an S. aureus alpha-toxin antigen and a pharmaceutically acceptable carrier are provided, and are useful for treating and preventing infections. The S. aureus alpha-toxin antigen may contain at least two alterations that reduce its toxicity and/or may be conjugated to or co-administered with another bacterial antigen. The vaccines may comprise one or more other bacterial antigens. Antibody compositions comprising antibodies to alpha-toxin and optionally one or more other bacterial antigens also are provided, and are useful for treating and preventing infections.
    Type: Application
    Filed: October 1, 2012
    Publication date: August 9, 2018
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventor: GlaxoSmithKline Biologicals S.A.
  • Vaccine compositions comprising a saponin adjuvant
    Patent number: 10039823
    Abstract: The present invention provides a human dose of an immunogenic composition comprising an antigen or antigenic preparation, in combination with an adjuvant which adjuvant comprises an immunologically active saponin fraction derived from the bark of Quillaja Saponaria Molina presented in the form of a liposome and a lipopolysaccharide wherein said saponin fraction and said lipopolysaccharide are both present in said human dose at a level of below 30 ?g. The present invention further provides an adjuvant composition in a human dose suitable volume comprising between 1 and 30 ?g of a lipopolysaccharide and between 1 and 30 ?g of an immunologically active saponin fraction presented in the form of a liposome.
    Type: Grant
    Filed: February 3, 2011
    Date of Patent: August 7, 2018
    Assignee: GlaxoSmithKline Biologicals, S.A.
    Inventor: Pierre Vandepapeliere
  • PHARMACEUTICAL COMPOSITION COMPRISING AN ADENOVIRAL VECTOR
    Publication number: 20180214379
    Abstract: The present invention relates to the formulation of Adenoviral vectors in an aqueous mixture or freeze dried composition in the presence of amorphous sugar and low salt concentration, its formulation as well as a method for obtaining the dried composition.
    Type: Application
    Filed: July 20, 2016
    Publication date: August 2, 2018
    Applicant: GlaxoSmithKline Biologicals, S.A.
    Inventors: Erwan BOURLES, Frederic MATHOT
  • Oil-in-water emulsion influenza vaccine
    Patent number: 10016495
    Abstract: The present invention provides an immunogenic influenza composition in a dose volume suitable for human use, comprising an influenza virus antigen or antigenic preparation thereof and an adjuvant composition comprising an oil-in-water emulsion, wherein said oil-in-water emulsion comprises a metabolisable oil at a level of below 11 mg and an emulsifying agent at a level of below 5 mg and optionally a tocol or a sterol at a level of below 12 mg. Suitably the amount of influenza antigen per strain per dose is 15 ?g HA or a low amount such as less than 15 ?g HA.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: July 10, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: William Ripley Ballou, Emmanuel Jules Hanon
  • Expression system
    Patent number: 9994622
    Abstract: Compositions and methods related to periplasmic expression of a toxin including diphtheria toxin or CRM197 are provided herein.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: June 12, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Normand Blais, Philippe Marc Helene Dehottay, Marianne Dewerchin, Philippe Goffin, Denis Martin
  • Influenza antigens and antibodies
    Patent number: 9975925
    Abstract: Novel influenza antigens, novel immunogenic or vaccine compositions, as well as uses of and methods for producing said antigens and compositions, are described.
    Type: Grant
    Filed: August 26, 2014
    Date of Patent: May 22, 2018
    Assignees: GLAXOSMITHKLINE BIOLOGICALS S.A., THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPT. HEALTH & HUMAN SERVICES
    Inventors: James Stevens, Ruben Donis, David Shore, Hongquan Wan, Ventzislav Bojidarov Vassilev
  • Influenza vaccine
    Patent number: 9943588
    Abstract: The present invention relates to monovalent influenza vaccine formulations and vaccination regimes for immunising against influenza disease, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation. In particular, the invention relates to monovalent influenza immunogenic compositions comprising an influenza antigen or antigenic preparation thereof from an influenza virus strain being associated with a pandemic outbreak or having the potential to be associated with a pandemic outbreak, in combination with an oil-in-water emulsion adjuvant comprising a metabolisable oil, a sterol and/or a tocopherol such as alpha tocopherol, and an emulsifying agent.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: April 17, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Emmanuel Jules Hanon, Jean Stephenne